SLS
SELLAS Life Sciences Group, Inc.
$11.54
+1.67%
2026-10-23
About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Key Fundamentals
Forward P/E
-116.10
EPS (TTM)
$-0.22
ROE
-39.6%
Profit Margin
0.0%
Debt/Equity
0.54
Price/Book
17.02
Beta
2.52
Market Cap
$2.34B
Avg Volume (10D)
7.5M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$15.67
60D Low
$9.75
Avg Volume
6.4M
Latest Close
$11.54
Get breakout alerts for SLS
Sign up for Breakout Scanner to receive daily notifications when SLS triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
SELLAS Life Sciences Group, Inc. (SLS) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors SLS daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. SLS operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.